- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
Patent holdings for IPC class A61K 31/472
Total number of patents in this class: 1270
10-year publication summary
|
70
|
76
|
94
|
101
|
112
|
102
|
95
|
76
|
75
|
71
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Xenon Pharmaceuticals Inc. | 195 |
28 |
| Alcon, Inc. | 5895 |
23 |
| The Regents of the University of California | 20815 |
18 |
| Astellas Pharma Inc. | 1039 |
16 |
| Ardelyx, Inc. | 119 |
15 |
| Eli Lilly and Company | 4101 |
15 |
| FibroGen, Inc. | 74 |
13 |
| Janssen Pharmaceutica N.V. | 3160 |
12 |
| Celgene Quanticel Research, Inc. | 154 |
12 |
| Novartis AG | 10173 |
10 |
| sanofi-aventis | 294 |
10 |
| Cornell University | 3441 |
8 |
| Kallyope, Inc. | 67 |
8 |
| Shanghai Zhimeng Biopharma Inc. | 34 |
8 |
| Kyntra Bio, Inc. | 51 |
8 |
| Boehringer Ingelheim International GmbH | 4486 |
7 |
| Vertex Pharmaceuticals Incorporated | 1579 |
7 |
| Actelion Pharmaceuticals Ltd | 489 |
7 |
| Epizyme, Inc. | 360 |
7 |
| Kowa Company, Ltd. | 1241 |
7 |
| Other owners | 1031 |